| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | CAROGEN CORP | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R43IP001228 | PA-21-259, SBIR, Phase I, Self-Amplifying RNA Replicon-Based Platform for Generating Multivalent Influenza Vaccine | 02 | 1 | CDC | 9/6/2024 | $0 |
| | 2024 | 2023 | CAROGEN CORP | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R43IP001228 | PA-21-259, SBIR, Phase I, Self-Amplifying RNA Replicon-Based Platform for Generating Multivalent Influenza Vaccine | 01 | 1 | CDC | 4/23/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,404,291 ) |
| | 2023 | 2023 | CAROGEN CORP | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R43IP001228 | PA-21-259, SBIR, Phase I, Self-Amplifying RNA Replicon-Based Platform for Generating Multivalent Influenza Vaccine | 00 | 1 | CDC | 8/30/2023 | $263,991 |
| | 2023 | 2023 | CAROGEN CORP | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R44DK113858 | GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | 000 | 6 | NIH | 4/12/2023 | $1,140,300 |
|
| Issue Date FY: 2022 ( Subtotal = $954,675 ) |
| | 2022 | 2022 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R44DK113858 | GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | 000 | 5 | NIH | 4/5/2022 | $954,675 |
| | 2022 | 2020 | CAROGEN CORP | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R43AI149798 | VLVs as platform for nucleic acid-based delivery:Combining therapeutic vaccine with shRNA-mediated PD-L1 blockade for the treatment of chronic hepatitis B virus | 000 | 1 | NIH | 6/3/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $939,695 ) |
| | 2021 | 2021 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R44DK113858 | GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | 000 | 4 | NIH | 5/10/2021 | $939,695 |
|
| Issue Date FY: 2020 ( Subtotal = $1,068,496 ) |
| | 2020 | 2020 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R44DK113858 | GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | 000 | 3 | NIH | 3/26/2020 | $768,496 |
| | 2020 | 2020 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R44DK113858 | GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | 001 | 3 | NIH | 4/3/2020 | $1,710 |
| | 2020 | 2020 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R43AI149798 | VLVs as platform for nucleic acid-based delivery:Combining therapeutic vaccine with shRNA-mediated PD-L1 blockade for the treatment of chronic hepatitis B virus | 000 | 1 | NIH | 9/14/2020 | $300,000 |
| | 2020 | 2018 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R43DK113858 | Enhancing Immunogenicity of VLV-Based Vaccines for Treatment of Chronic HBV | 000 | 1 | NIH | 3/30/2020 | -$1,710 |
|
| Issue Date FY: 2019 ( Subtotal = $615,763 ) |
| | 2019 | 2019 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R44DK113858 | GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | 000 | 2 | NIH | 3/26/2019 | $615,763 |
| | 2019 | 2018 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R43DK113858 | Enhancing Immunogenicity of VLV-Based Vaccines for Treatment of Chronic HBV | 000 | 1 | NIH | 3/21/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $224,710 ) |
| | 2018 | 2018 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R43DK113858 | Enhancing Immunogenicity of VLV-Based Vaccines for Treatment of Chronic HBV | 001 | 1 | NIH | 6/7/2018 | -$224,710 |
| | 2018 | 2018 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R43DK113858 | Enhancing Immunogenicity of VLV-Based Vaccines for Treatment of Chronic HBV | 001 | 1 | NIH | 6/7/2018 | $224,710 |
| | 2018 | 2018 | CAROGEN CORPORATION | 295 WASHINGTON AVE | HAMDEN | CT | 06518-3025 | SOUTH CENTRAL CT | USA | R43DK113858 | Enhancing Immunogenicity of VLV-Based Vaccines for Treatment of Chronic HBV | 000 | 1 | NIH | 6/5/2018 | $224,710 |
|
|
